

AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595

RECEIVED
CENTRAL FAX CENTER
JUL 14 2009


Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1.- 46. (Cancelled)

47. (Currently amended) A compound of formula (I), or a pharmaceutically acceptable salt thereof



(I)

wherein

X and X' taken together form -C(R₅)=N-;

Y is -C(R₅)- and taken together with the carbon atom bearing the phenyl group forms a double bond and R₁ is absent;

Y' is -N(R₅)-;

Z forms a covalent single bond between X' and Y';

R₂ and R₄ are independently selected from hydrogen and C₁₋₃alkyl;

R₃ is selected from C₁₋₃alkyl and (A)_mR₁₂;

-C(R₅)- is selected from -C(H)- and -C(C₁₋₂₀alkyl)-;

-N(R₅)- is selected from -N(H)- and -N(C₂₋₂₀alkyl)-;

m is 0;


R₁₂ is selected from the group consisting of OH, SH, NH₂, halo, NO₂, C(R₁₇)₃,

AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595

$OC(R_{17})_3$ and CN ; and

R_{17} is independently selected from hydrogen and halogen.

48. (Previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof



(I)

wherein

X and X' taken together form $-C(R_5)=N-$;

Y is $-C(R_5)-$ and taken together with the carbon atom bearing the phenyl group forms a double bond and R_1 is absent;

Y' is $-N(R_5)-$;

Z forms a covalent single bond between X' and Y' ;

R_2 and R_4 are independently selected from hydrogen and C_{1-3} alkyl;

R_3 is selected from C_{1-3} alkyl and $(A)_mR_{12}$;

$-C(R_5)-$ is selected from $-C(H)-$ and $-C(C_{1-20}alkyl)-$;

$-N(R_5)-$ is selected from $-N(alkyl)-$ wherein alkyl is selected from the group consisting of ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, t-butyl, cyclobutyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1-propylpropyl, 2-propylpropyl and cyclohexyl;

m is 0;

R_{12} is selected from the group consisting of OH , SH , NH_2 , halo, NO_2 , $C(R_{17})_3$,

AMENDMENT AND RESPONSE TO OFFICE ACTION
U.S.S.N. 10/522,595

OC(R₁₇)₃ and CN;
R₁₇ is independently selected from hydrogen and halogen; and
wherein each alkyl may be optionally substituted.

49. (Currently amended) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein
Y is -CH-; and
X is -CH-.

50. (Currently amended) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is OC(R₁₇)₃.

51. (Currently amended) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is C₁₋₃alkyl.

52. (Currently amended) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein R₃ is -CH₃ or -OCH₃.

53. (Currently amended) The compound according to claim 47 or claim 48, or a pharmaceutically acceptable salt or prodrug thereof, wherein N(R₅)- is -N(3-methylbutyl).

54. (Currently amended) A compound wherein the compound is 4-(4-methoxyphenyl)-1-(3-methylbutyl)-1*H*-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

55. (Currently amended) A compound wherein the compound is 1-(3-methylbutyl)-4-(4-methylphenyl)-1*H*-pyrazole or a pharmaceutically acceptable salt or prodrug thereof.

56. (Previously presented) A pharmaceutical composition comprising a compound according to any one of claims 47, 48, 54 or 55, and a pharmaceutically acceptable carrier, diluent or excipient.

57. (Previously presented) The pharmaceutical composition according to claim 56 further comprising a glucocorticoid.